

REMARKS

I. Discussion of the Rejection for Obviousness-Type Double Patenting

Claims 8-24 have been rejected under the judicially-created doctrine of double patenting obviousness-type double patenting as allegedly unpatentable over claims 1-6 of U.S. Patent No. 6,664,276 and claims 1-8 of U.S. Patent No. 6,462,058 in view of Hirschowitz (CA 125:185465).

Terminal Disclaimers over each of the patents cited by the Examiner accompany this response. Therefore Applicants respectfully request withdrawal of the rejection for obviousness-type double patenting.

Applicants note that on page 2 of the Office Action, U.S. Patent No. 5,462,058 was referenced instead of U.S. Patent No. 6,462,058. However, due to the listing of U.S. Patent No. 6,462,058 on the form PTO-892, Applicants believe that the citation on page 2 is a typographical error. Should this not be so, Applicants respectfully request that the Examiner inform them.

II. Conclusion

Reconsideration of the claims and allowance is requested.
Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully invited to call Applicants' attorney at the number below.

Respectfully submitted,

Dated: December 21, 2004

(847) 383-3391

(847) 383-3372

Elaine M Ramesh
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Mark Chao, Ph.D., Reg. No. 37,293
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
475 Half Day Road
Lincolnshire, IL 60069 USA

Certificate of Mailing under 37 CFR 1.10

The undersigned hereby certifies that this document, along with any attachments, is being deposited in an envelope addressed to The Commissioner of Patents and Trademarks, with sufficient postage with the United States Postal Service EXPRESS MAIL Post Office to Addressee Service on this date 12/21/2004.

Express Mail Label No. EV 524906858 US

Gail L. Winokur

Printed Name: Gail L. Winokur